|
|||||
| |
Germ of the Month - July 2005
An international outbreak of severe acute respiratory syndrome, caused by a newly identified coronavirus, began in November 2002 and ended in July 2003. The 2002-2003 outbreak probably originated from animal-to-human transmission, most likely civet cats, creating the more virulent severe acute respiratory syndrome-associated coronavirus we know of as SARS.1 Recent studies have documented that severe acute respiratory syndrome-associated coronavirus is primarily transmitted via contact and/or respiratory droplets and that the combination of standard, contact, and droplet precautions is generally effective for its control.2 Promising treatments have been identified, including interferons, an anti-spike monoclonal antibody, and fusion inhibitors. In addition, many promising vaccines are currently in development.3 SARS alerted the general population to the formidable challenges facing the global healthcare community and the impact of travel to the spread of infectious disease. All countries have to be prepared at a number of levels to deal with the threat posed by the SARS epidemic and any other emerging infectious disease. The healthcare sector should consider a few issues:
We hope you enjoy introducing your staff to Shari this month as you continue your own efforts to educate and maintain awareness about infectious disease in your facility. This information is brought to you by Regent Medical, maker of Hibiclens® antiseptic and Hibistat®, convenient antimicrobial towelettes with the persistence of CHG.5 Our reason for all that we do is to provide you with the very best in products and support, to help you control infections. We look forward to hearing from you about our Hibigeebie® campaign. Please feel free to contact us at 1-800-843-8497.
1 Poutanen SM, Low DE. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis. 2004 Aug;17(4):287-94. 2 Poutanen SM, Low DE. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis. 2004 Aug;17(4):287-94. 3 Poutanen SM, Low DE. Severe acute respiratory syndrome: an update. Curr Opin Infect Dis. 2004 Aug;17(4):287-94. 4 Abdullah ASM, Tomlinson B, Cockram CS,Thomas GN. Lessons from the Severe Acute Respiratory Syndrome Outbreak in Hong Kong. Emerging Infectious Diseases 2003; 9(9). 5 Regent Medical urges all users to read the product leaflet closely and use Hibi products only as directed. |
|
|||
Hibiclens, the Hibiclens logo, Hibistat, the Hibistat logo, Hibigeebies, the Mölnlycke logo, and Mölnlycke are registered trademarks of Mölnlycke Group of companies. Distributed by Mölnlycke Health Care US, LLC, Norcross, Georgia 30092. ©2007 Mölnlycke Health Care AB. All rights reserved. 1.800.843.8497 www.molnlycke.com |
|||||
| |
|||||